Arrowhead Pharma stock price target raised to $85 by H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $85 from $80 on Wednesday, while maintaining a Buy rating on the stock following the recent approval of REDEMPLO. This target matches the highest analyst price projection for the company, which currently has a consensus recommendation of 1.77 (Buy) according to InvestingPro data.

The firm views the newly approved REDEMPLO (plozasiran) label as "best-in-class" across safety, convenience, and intent-to-treat population breadth, supporting an initial launch focused on the FCS rare indication while establishing groundwork for expansion into high-risk severe hypertriglyceridemia (sHTG) in 2027.

Top-line readouts from the sHTG Phase 3 trials SHASTA-3, SHASTA-4, and MUIR-3 remain on track for the third quarter of 2026, with management expressing confidence these will achieve meaningful triglyceride lowering and supportive pancreatitis trends. Investors tracking these catalysts can access Arrowhead’s comprehensive financial health metrics through InvestingPro, which rates the company’s overall financial condition as "GREAT" with a score of 3.33.

Arrowhead is expanding its late-stage cardiometabolic portfolio with the ongoing pivotal zodasiran program in homozygous familial hypercholesterolemia and the advancement of ARO-DIMER-PA to Phase 1/2 development, announced on October 7, with initial data expected in summer 2026.

Since REDEMPLO’s approval on November 18, Arrowhead shares have risen approximately 40% compared to the XBI index’s 5% gain, with the drug’s launch now underway and multiple pivotal datasets approaching. This surge contributes to the stock’s impressive 248.89% return over the past six months and 122.29% over the last year, according to InvestingPro data. With shares trading near their 52-week high of $59.27 and RSI indicating overbought territory, investors should note that analysts anticipate a sales decline in the current year, with the next earnings report due February 10, 2026.

In other recent news, Arrowhead Pharmaceuticals reported its fourth-quarter 2025 earnings, showing a net loss of $2 million, or $0.01 per share, with revenue reaching $829 million. The revenue was primarily driven by licensing agreements. This financial report comes as Arrowhead transitions to a commercial-stage entity, supported by the FDA approval of Redemplo for Familial Chylomicronemia Syndrome. Additionally, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Arrowhead’s drug plozasiran for treating severe hypertriglyceridemia. In another development, BofA Securities raised its price target for Arrowhead Pharmaceuticals to $62.00 from $42.00, maintaining a Buy rating. This adjustment reflects the clinical progress in Arrowhead’s obesity and neuromuscular programs. These developments highlight the company’s ongoing advancements in its drug pipeline and strategic growth initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.